Sonire Therapeutics has been awarded a $13 million grant from Japan’s New Energy and Industrial Technology Development Organization (NEDO) to accelerate development of its Suizenji ultrasound-based treatment system for pancreatic cancer.
The funding comes through NEDO’s Deep-Tech Startups Support (DTSU) programme and will support manufacturing scale-up, regulatory activities in Japan, expansion into new clinical applications, and ongoing U.S. clinical development.
Related: Icarus Medical secures $7.2M Series A to accelerate growth and innovation
Suizenji uses high-intensity focused ultrasound (HIFU) combined with real-time imaging and robotic positioning to deliver targeted thermal ablation of tumors without invasive surgery. The system received FDA breakthrough device designation in 2024 and is currently being evaluated in clinical trials for patients with unresectable pancreatic cancer.
CEO Tohru Satoh said:
“This funding will help accelerate our clinical development, regulatory activities, manufacturing readiness, and commercialisation efforts in both Japan and the United States.”
The grant follows Sonire’s $18 million Series A financing earlier in 2026 and supports the company’s goal of bringing a non-invasive treatment option to patients with one of the most challenging cancers to treat.
